title: Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
abstract: BACKGROUND
  Pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) is considered a surrogate for improved survival. Platinum-containing NCT, particularly in patients with HER2+ and triple-negative breast cancers (TNBC) may increase pCR rates.
  
  
  METHODS
  Tumor characteristics, pCR rates (no invasive disease in breast and lymph nodes), toxicities, and survival in patients who received carboplatin, a taxane, and trastuzumab (HER2+ disease) between April 2009 and December 2011, were reviewed.
  
  
  RESULTS
  Thirty eight patients (39 tumors) completed a median of 4 cycles of NCT. Eighteen of 39 (46%) tumors were HER2+, 8/18 (44%) responded with pCR; 13/18 HER2+ tumors were HR+ (72%) and 4/13 (31%) had a pCR. Ten of 39 (26%) tumors were TNBC; 6/10 (60%) had a pCR. At a median of 25-months no recurrences were observed in patients with pCR.
  
  
  CONCLUSIONS
  Prospective studies of anthracycline-free platinum-containing NCT are warranted in LABC patients with HER2+ and TNBC.
authors.affiliation: Department of Medical Oncology and Therapeutic Research, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA.
authors.forename: Arvind M
authors.initials: AM
authors.lastname: Shinde
authors.affiliation: Department of Pathology, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhai
authors.affiliation: Department of Clinical Pharmacy, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA.
authors.forename: Kim Wai
authors.initials: KW
authors.lastname: Yu
authors.affiliation: Department of Information Sciences, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Frankel
authors.affiliation: Department of General Oncologic Surgery, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA.
authors.forename: John H
authors.initials: JH
authors.lastname: Yim
authors.affiliation: Department of Medical Oncology and Therapeutic Research, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA.
authors.forename: Thehang
authors.initials: T
authors.lastname: Luu
authors.affiliation: Department of General Oncologic Surgery, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA.
authors.forename: Laura
authors.initials: L
authors.lastname: Kruper
authors.affiliation: Department of General Oncologic Surgery, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA.
authors.forename: Courtney
authors.initials: C
authors.lastname: Vito
authors.affiliation: Department of Diagnostic Radiology, City of Hope, 1500 East Duarte Rd., Duarte, CA, 91010 USA.
authors.forename: Sally
authors.initials: S
authors.lastname: Shaw
authors.affiliation: Department of Diagnostic Radiology, City of Hope, 1500 East Duarte Rd., Duarte, CA, 91010 USA.
authors.forename: Nayana L
authors.initials: NL
authors.lastname: Vora
authors.affiliation: Office of Clinical Trials, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA.
authors.forename: Michele
authors.initials: M
authors.lastname: Kirschenbaum
authors.affiliation: Department of Medical Oncology and Therapeutic Research, City of Hope, 1500 East Duarte Rd., Duarte, CA 91010, USA. Electronic address: GSomlo@coh.org.
authors.forename: George
authors.initials: G
authors.lastname: Somlo
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology*; D017239:Paclitaxel / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D012189:Retrospective Studies; D000068878:Trastuzumab; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy / Q000473:pathology
chemical_list: D018943:Anthracyclines; D061067:Antibodies, Monoclonal, Humanized; D016190:Carboplatin; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000068878:Trastuzumab; C508053:ERBB2 protein, human
keywords: Carboplatin; Human epidermal growth factor receptor 2 (HER2); Inflammatory breast cancer; Locally advanced breast cancer (LABC); Pathologic complete response (pCR); Triple-negative breast cancer (TNBC)